FDA May Expand EUA of Pfizer Vaccine to Include 12-15 Year Olds

May 4, 2021

In March, Pfizer released the results of a clinical trial announcing that their COVID-19 vaccine displayed 100% efficacy in adolescents ages 12-15 years of age. The FDA has been reviewing the results of this Phase 3 trial, and an amendment to the current Emergency Use Authorization (EUA) of Pfizer’s vaccine is said to be determined next week. While 22% of the U.S. population is composed of children under 18 years of age, Pfizer is the only vaccine manufacturer in the U.S. currently authorized for ages 16-18. If the EUA is amended, Pfizer will be the first vaccine manufacturer authorized for use in people ages 12-18.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.